An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, n...
RAS Drug Nearly Doubles Survival in Mets Pancreatic Cancer
An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common...
Author: Medscape
Read Original Article